Maze Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 that develops small-molecule precision medicines by leveraging human genetics. The company uses its proprietary Maze Compass platform, which integrates human genetics and functional genomics, to identify and validate therapeutic targets. This approach aims to translate genetic insights into targeted treatments for specific patient populations.
The company is advancing three clinical-stage therapeutic programs and several drug discovery programs focused on renal diseases, cardiovascular diseases, and related metabolic conditions. Its scientific foundation rests on applying translational genetics and functional genomics to drug discovery and clinical development, enabling the identification of novel targets that might otherwise remain hidden.
